Neurogene (NGNE) Tax Provisions (2013 - 2014)
Neurogene posted quarterly Tax Provisions of -$222.0 for Q3 2014, up 95.6% year-on-year from -$113.5 in Q3 2013, and down 604.55% on a QoQ basis from $44.0 in Q4 2013.
Neurogene (NGNE) has 2 years of Tax Provisions data on file, last reported at -$222.0 in Q3 2014.
- For the quarter ending Q3 2014, Tax Provisions rose 95.6% year-over-year to -$222.0; the trailing twelve-month figure through Dec 2014 stood at -$5222.0 (changed N/A YoY), and the FY2014 full-year result was -$222.0, up 95.56% from the prior year.
- Tax Provisions for Q3 2014 stood at -$222.0, down from $44.0 in the prior quarter.
- Across five years, Tax Provisions topped out at $44.0 in Q4 2013 and bottomed at -$5044.0 in Q3 2013.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -11.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -859,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 221.50 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 216,000.00 |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 15.66 Mn |
| 10 | Neurogene | 632.14 Mn | 632.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2014 | -222.00 |
| Dec 31, 2013 | 44.00 |
| Sep 30, 2013 | -5,044.00 |